<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30290620</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>23</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>23</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1536-5964</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>97</Volume>                    <Issue>40</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>Medicine</Title>                <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>            </Journal>            <ArticleTitle>99mTc-MIBI single photon emission computed tomography/computed tomography for the incidental detection of rare parathyroid carcinoma.</ArticleTitle>            <Pagination>                <MedlinePgn>e12578</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000012578</ELocationID>            <Abstract>                <AbstractText>This study aimed to evaluate the characteristics of parathyroid carcinoma and to validate the diagnostic value of Tc-methoxyisobutylisonitrile (MIBI) single photon emission computed tomography/x-ray computed tomography (SPECT/CT) for differentiating between parathyroid carcinoma and hyperparathyroidism. Four consecutive patients with suspected primary hyperparathyroidism were enrolled in this study and underwent Tc-MIBI SPECT/CT, ultrasonography, enhanced CT, and MRI. Serum parathyroid hormone (PTH) and calcium were measured. All primary and recurrent lesions showed high focal uptake on Tc-MIBI image, whereas metastatic lymph nodes gave false negative results. The serum PTH was 165.14 ± 90.26 pmol/L, which declined rapidly after surgery. One patient with a persistently high PTH (147.5 pmol/L) after surgery presented with multiple lymphadenopathy in the neck. Higher expression of chromogranin A (CgA) further confirmed parathyroid carcinoma as a rare endocrine tumor. Parathyroid carcinoma is thus usually diagnosed incidentally based on nonspecific multiorgan symptoms of hypercalcemia and hyperparathyroidism. Tc-MIBI SPECT/CT may help to localize the parathyroid carcinoma, while MRI is valuable for detecting metastasis. Serum PTH and CgA serve as circulating biomarkers in parathyroid carcinoma, and raised levels of PTH and CgA together with locoregional lymphadenopathy may indicate parathyroid carcinoma. Further studies are needed.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Chen</LastName>                    <ForeName>Zejun</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Nuclear Medicine.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fu</LastName>                    <ForeName>Jingjing</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shao</LastName>                    <ForeName>Qing</ForeName>                    <Initials>Q</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thyroid and Breast Surgery, Affiliated Jiangyin Hospital of Southeast University, Jiangyin, Jiangsu, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhou</LastName>                    <ForeName>Bin</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thyroid and Breast Surgery, Affiliated Jiangyin Hospital of Southeast University, Jiangyin, Jiangsu, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Feng</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D064888">Observational Study</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Medicine (Baltimore)</MedlineTA>            <NlmUniqueID>2985248R</NlmUniqueID>            <ISSNLinking>0025-7974</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D053379">Chromogranin A</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D010281">Parathyroid Hormone</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>971Z4W1S09</RegistryNumber>                <NameOfSubstance UI="D017256">Technetium Tc 99m Sestamibi</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>SY7Q814VUP</RegistryNumber>                <NameOfSubstance UI="D002118">Calcium</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>AIM</CitationSubset>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName>                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D053379" MajorTopicYN="N">Chromogranin A</DescriptorName>                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005188" MajorTopicYN="N">False Negative Reactions</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006961" MajorTopicYN="N">Hyperparathyroidism</DescriptorName>                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName>                <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D064847" MajorTopicYN="N">Multimodal Imaging</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D010281" MajorTopicYN="N">Parathyroid Hormone</DescriptorName>                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D010282" MajorTopicYN="N">Parathyroid Neoplasms</DescriptorName>                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>                <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName>                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000072098" MajorTopicYN="N">Single Photon Emission Computed Tomography Computed Tomography</DescriptorName>                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017256" MajorTopicYN="N">Technetium Tc 99m Sestamibi</DescriptorName>                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>7</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>7</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30290620</ArticleId>            <ArticleId IdType="doi">10.1097/MD.0000000000012578</ArticleId>            <ArticleId IdType="pii">00005792-201810050-00034</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>